|Videos|October 14, 2021
Dr. Stewart assesses novel renal cancer treatment
Author(s)Urology Times staff
“Clearly, we are now in that era of TKIs in addition to checkpoint inhibitors, and so…it makes logical sense from the place we're at [in] the moment in renal cancer treatment with those combinations of treatment,” says Grant Stewart, MD.
Advertisement
In this video, Grant Stewart, MD, discusses future research based on the results from the study, “NAXIVA – a phase II neoadjuvant study of axitinib for reducing extent of venous tumor thrombus in clear cell renal cell cancer with venous invasion: translational results.” Stewart is a professor of surgical oncology and honorary consultant urological surgeon at the University of Cambridge, England, United Kingdom.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants clearance to Hugo robotic-assisted surgery system for urologic procedures
2
Apalutamide is linked to fewer CNS-related conditions in patients with nmCRPC
3
Prostate MRI is linked with higher sensitivity, NPV vs micro-ultrasound in pilot study
4
BOND-003: Cretostimogene yields durable 24-month responses in high-grade NMIBC
5
